Investment objective & strategy
As of Oct. 22, 2025 · prospectusObjective. The fund seeks long-term capital appreciation .
Strategy. The fund pursues long-term capital appreciation in health sciences-related companies. The fund invests in a select group of health science-related companies believed by the funds subadviser to possess sustainable competitive advantages at prices the subadviser deems attractive. The fund seeks to achieve its objective by normally investing at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. The fund considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The fund will invest primarily in common stocks and other equity securities. Although the fund may invest in companies of any market capitalization, the fund does not currently … The fund pursues long-term capital appreciation in health sciences-related companies. The fund invests in a select group of health science-related companies believed by the funds subadviser to possess sustainable competitive advantages at prices the subadviser deems attractive. The fund seeks to achieve its objective by normally investing at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. The fund considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The fund will invest primarily in common stocks and other equity securities. Although the fund may invest in companies of any market capitalization, the fund does not currently intend to invest more than 15% of its assets in companies with market capitalizations below $1 billion. The fund may invest in U.S. and non-U.S. companies. The fund may invest in securities issued in initial public offerings (IPOs). Generally, the fund invests in approximately 25 to 40 securities at any given time.
Top holdings
As of March 31, 2026 · N-PORT| Security | Ticker | Value | % of fund |
|---|---|---|---|
| LILLY ELI and CO | — | $11.94M | 13.30% |
| MCKESSON CORP | — | $5.00M | 5.57% |
| VERTEX PHARMACEUTICALS INC | — | $4.57M | 5.09% |
| ABBVIE INC | — | $4.57M | 5.09% |
| MERCK & CO | — | $4.53M | 5.05% |
| INTUITIVE SURGICAL INC | — | $4.31M | 4.80% |
| WEST PHARMACEUTICAL SVCS INC | — | $3.95M | 4.40% |
| IDEXX LABS INC | — | $3.85M | 4.29% |
| METTLER-TOLEDO INTL INC | — | $3.77M | 4.20% |
| COOPER COS INC | — | $3.63M | 4.05% |
Portfolio moves
Dec 31, 2025 → Mar 31, 2026How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.
Similar funds
Funds whose portfolios most overlap this one, by weight| Fund | Overlap | Net exp. |
|---|---|---|
| State Street(R) Health Care Select Sector SPDR(R) ETF · XLV | 48% | 0.08% |
| PROFUND VP HEALTH CARE | 47% | 1.68% |
| DWS Health and Wellness Fund · SUHAX, SUHCX, SCHLX, SUHIX | 46% | 1.03% |
Advisers
| Firm | Role |
|---|---|
| Virtus Investment Advisers, LLC | Adviser |
| Kayne Anderson Rudnick Investment Management, LLC | Sub-adviser |
Footnotes
- Net assets and holdings count as of March 31, 2026, from the fund's N-PORT filing.
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.